1-9 of 9
Martin Soekler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Sarah Reinke, Paul J. Bröckelmann, Ingram Iaccarino, Maria Garcia-Marquez, Sven Borchmann, Franziska Jochims, Michaela Kotrova, Karol Pal, Monika Brüggemann, Elena Hartmann, Stephanie Sasse, Carsten Kobe, Stephan Mathas, Martin Soekler, Ulrich Keller, Matthias Bormann, Andreas Zimmermann, Julia Richter, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Hans Schlößer, Michael von Bergwelt-Baildon, Andreas Rosenwald, Andreas Engert, Wolfram Klapper
Journal: Blood
Blood (2020) 136 (25): 2851–2863.
https://doi.org/10.1182/blood.2020008553
Published: 2020
Includes: Supplemental data
Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert
Journal: Blood
Blood (2015) 126 (23): 580.
https://doi.org/10.1182/blood.V126.23.580.580
Published: 2015
Journal Articles

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, MD, Anna Maria Fink, MD, Raymonde Busch, Gabor Kovacs, MD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael G Kiehl, MD, Martin Soekler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg R.A. Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, MD PhD, Clemens-Martin Wendtner, MD, Wolfram Klapper, MD, Karl Anton Kreuzer, Prof. Dr. MD, Stephan Stilgenbauer, MD PhD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 19.
https://doi.org/10.1182/blood.V124.21.19.19
Published: 2014
Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2013) 122 (21): 4344.
https://doi.org/10.1182/blood.V122.21.4344.4344
Published: 2013
Journal Articles

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Clinical Trials & Observations
Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans T. Eich, Martin Soekler, Jana Markova, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geissler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2011) 118 (24): 6292–6298.
https://doi.org/10.1182/blood-2011-07-368167
Published: 2011
Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Andreas Viardot, MD, Mariele Goebeler, MD, Richard Noppeney, MD, Stefan W. Krause, MD, Stefan Kallert, MD, Barbara Ferstl, MD, Andreas Mackensen, Kathrin Rupertus, MD, Martin Soekler, MD, Lothar Kanz, MD, Stefan Knop, MD, Max S. Topp, MD, Jurgen Scheele, MD, PhD, Dirk Nagorsen, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Margit Schmidt, PhD, Peter Kufer, MD, Martin Libicher, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2011) 118 (21): 1637.
https://doi.org/10.1182/blood.V118.21.1637.1637
Published: 2011
Journal Articles

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Andreas Engert, MD, Peter Borchmann, MD, Annette Pluetschow, Bastian von Tresckow, Jana Markova, Felicitas Hitz, Zdenek Kral, Richard Greil, MD, Max S Topp, Matthias Villalobos, Josee M. Zijlstra, Martin Soekler, Harald Stein, MD, Hans-Theodor Eich, Rolf-Peter Mueller, Michael Fuchs, Volker Diehl
Journal: Blood
Blood (2010) 116 (21): 765.
https://doi.org/10.1182/blood.V116.21.765.765
Published: 2010
Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl
Journal: Blood
Blood (2008) 112 (11): 367.
https://doi.org/10.1182/blood.V112.11.367.367
Published: 2008
Journal Articles

A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, STefan W. Krause, MD, PhD, Marion Subklewe, MD, Judith Kruse, MD, Martin Soekler, MD, Katja Weisel, MD, Soo-Zin Kim, MD, Martin H. Dreyling, MD, PhD, Elke Jager, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2721.
https://doi.org/10.1182/blood.V108.11.2721.2721
Published: 2006